Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ultragenyx sells Mepsevii PRV to Novartis for $130mm

Executive Summary

Ultragenyx Pharmaceutical Inc. sold Novartis AG its rare pediatric disease priority review voucher (PRV), which the FDA awarded to Ultragenyx last month upon approval of its enzyme replacement therapy Mepsevii (vestronidase alfa) for the rare genetic, metabolic lysosomal storage disorder mucopolysaccharidosis VII (MPS VII; otherwise known as Sly syndrome). Mepsevii, originally licensed from St. Louis University in 2012, is designed to replace the deficient lysosomal enzyme beta-glucuronidase (required for the breakdown of certain carbohydrates) in both adult and children with MPS VII.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other

Related Companies